Bolivia vs Zambia: Average cost of drugs for extensively drug-resistant tuberculosis
Bolivia
753 constant 2022 US$
in 2024
Zambia
600 constant 2022 US$
in 2024
Bolivia rank
48th
Zambia rank
49th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Bolivia
- Zambia
How they compare
Bolivia currently reports 753 constant 2022 US$ against 600 constant 2022 US$ in Zambia, a difference of 153 constant 2022 US$.
That makes Bolivia's figure about 1.3 times Zambia's.
Across all 5 years both countries report, Bolivia has been ahead every year.
Bolivia ranks 48th and Zambia ranks 49th of 56 countries.
Bolivia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Bolivia | Zambia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 9,454 constant 2022 US$ | 6,240 constant 2022 US$ | 3,214 constant 2022 US$ | Bolivia |
| 2020s | 8,250 constant 2022 US$ | 3,280 constant 2022 US$ | 4,970 constant 2022 US$ | Bolivia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Bolivia or Zambia?
- Bolivia, at 753 constant 2022 US$ against 600 constant 2022 US$ in Zambia as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Bolivia and Zambia?
- 153 constant 2022 US$, with Bolivia ahead.
- How many years of comparable data are there for Bolivia and Zambia?
- 5 years are reported by both, from 2018 to 2024.
- How do Bolivia and Zambia rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Bolivia ranks 48th and Zambia ranks 49th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.